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whom both agents were orally administered.
Patients and Methods: Eighteen recipients of allogeneic HSCT
who had already been on a steady dose of oral calcineurin inhibitors
(CsA (n5 8) or tacrolimus (n5 10)), and were started on oral
voriconazole (200 mg per body every 12 h) for the treatment or
prophylaxis of fungal infection could be evaluated. The concentra-
tion/dose (C/D; (ng/ml)/(mg/kg)) ratio of calcineurin inhibitors
was calculated 7–10 days after initiating voriconazole when the in-
creased blood levels of calcineurin inhibitors had stabilized. The
plasma level of voriconazole was measure by high-performance
liquid chromatography.
Results: The median C/D ratios of CsA and tacrolimus signif-
icantly increased after initiating voriconazole as compared with
those before initiating voriconazole (P\0.05). Median increases
of C/D ratios after initiating voriconazole were 62.0% with
a range of 0% to 135.8% in CsA-administered patients, and
196.8% with a range of -32.0% to 400.0% in tacrolimus-admin-
istered patients, which tended to be higher in tacrolimus-admin-
istered patients (P5 0.068). The plasma level of voriconazole
measured 7–10 days after initiating voriconazole was
2.266 1.21 mg/ml, and exceeded 2.0 mg/ml in 12 patients
(66.7%). The increase in C/D ratio of CsA and tacrolimus after
initiating voriconazole did not correlate with the plasma level of
voriconazole.
Conclusion:Although calcineurin inhibitors and voriconazole dem-
onstrates a significant interaction when both agents are administered
orally, the magnitude of interaction differs widely among the pa-
tients, and is considered greater with tacrolimus than with CsA.
Since the interindividual difference was not due to the difference
in the bioavailability of oral voriconazole, other mechanisms should
be explored.279
THE UPDATED SCHWARTZ FORMULA AS A SCREENING TEST FOR ABNOR-
MAL KIDNEY FUNCTION PRIOR TO HEMATOPOIETIC STEM CELL TRANS-
PLANTATION
Qayed, M., Thompson, A., Applegate, K., Haight, A., Chiang, K.-Y.,
Horan, J. Emory University and Children’s Healthcare of Atlanta, GA
Assessing renal function is an integral part of evaluating pedi-
atric patients for hematopoietic stem cell transplantation
(HSCT). The most accurate method is DTPA-Tc-99m GFR test-
ing. It, however, is costly and time consuming. The Schwartz
formula, which was recently updated, represents an easy alterna-
tive. To determine the appropriateness of using the updated and
simplified Schwartz formula for pre-transplant screening for ab-
normal kidney function, we compared it to the results obtained
using DTPA-Tc-99m GFR testing, which we routinely perform
as part of our pre-transplant evaluation. We retrospectively re-
viewed the charts of 107 consecutive children over the age of
12 months who underwent HSCT between January 1, 2004
and June 30, 2006, including demographic data, serum creatinine
and DTPA-Tc-99m GFR, height, and primary diagnosis. GFR
was estimated using the updated Schwartz formula (0.413*height
in centimeters/Creatinine). Nuclear medicine measurement of
GFR was carried out using DTPA-Tc-99m per institutional pro-
tocol, and calculated GFR was corrected for body surface area.
The utility of using the calculated GFR as a screening test to
distinguish patients with abnormal GFR (\90 ml/min/1.73 m2)
was tested by Receiver operating characteristic (ROC) curve anal-
ysis. Cut-off points optimizing sensitivity and simultaneously op-
timizing both sensitivity and specificity were determined. There
were 56 males and 51 females. The mean age at transplantation
was 9.1 years (+/-5.8). Eighty five (79.4%) patients had malignan-
cies (table I). The mean estimates of GFR with DTPA-Tc-99m
and the updated formula were 106.62 (S.E, 628.35) and 96.48
(S.E., 626.10), respectively. The area under the curve for calcu-
lated GFR was 0.71 (P5 0.001). The GFR value optimizing both
was 87.4 ml/min/1.73 m2, with sensitivity 67.5% and specificity
64.4% (34% of patients misclassified). At a cut point of109 ml/min/1.73 m2, the sensitivity was 82.5%, however the
specificity was compromised at only 30.2%. The updated
Schwartz formula is a poor screening method for abnormal kid-
ney function in HSCT candidates. Nuclear medicine testing
maybe indicated, especially in heavily pretreated patients.280
PSYCHOSOCIAL FACTORS AS MEASURED BY THE TRANSPLANT EVALUA-
TION RATING SCALE (TERS) PREDICT LENGTH OF HOSPITALIZATION
AND INFECTIOUS COMPLICATIONS FOLLOWING HEMATOPOIETIC
STEM CELL TRANSPLANTATION
Speckhart, D.1, Bashey, A.1,2, Morris, L.E.1,2, Solomon, S.1,2, Berry, T.1,
Holland, H.K.1,2 1Blood and Marrow Transplant Program at Northside
Hospital, Atlanta, GA; 2Blood andMarrow Transplant Group of Georgia,
Atlanta, GA
Although psychological and social factors are recognized as
being important in the evaluation of patients for hematopoietic
stem cell transplantation (HSCT), no standard approach to psy-
chosocial assessment currently exists. In solid organ transplanta-
tion, psychosocial assessments have been integrated into the
selection of appropriate candidates, and certain psychosocial var-
iables, such as active substance abuse, have been shown to neg-
atively impact outcomes in solid organ transplant patients. To
determine whether similar factors impact outcomes in patients
undergoing HSCT, we prospectively conducted psychosocial as-
sessments on 155 consecutive patients undergoing autologous
HSCT primarily initiated in an outpatient setting. The relation-
ship between psychosocial variables, such as those assessed on
the Transplant Evaluation Rating Scale (TERS), and objective
outcomes, such as length of hospitalization and the number of
documented blood infections were evaluated. Based on the pa-
tient’s TERS score, each patient was stratified into one of
two groups (low/moderate risk (n5 134) vs. high risk (n5 21))
based on their predicted psychosocial risk for problems during
transplant. Although the two groups were similar in regards to
known pre-transplant prognostic factors such as age, perfor-
mance status, disease risk, and transplant type, there continues
to be a significant difference in the mean length of hospitaliza-
tion between patients who score low/moderate (10 days) and
those who scored high (16 days) on the TERS. Furthermore,
there was also a significant difference (p\.0001) in the total
number of blood infections per patient (48% of high risk pa-
tient had documented blood infections vs. 39% of low/moderate
risk patients had documented blood infections) based on their
TERS score. This data also revealed a significant difference in
the total number of blood infections over all between groups
(p\.0001). Although psychosocial factors appear to influence
a patient’s process during HSCT, it is not clear what particular
psychosocial factor most impacts these objective outcomes.
These findings suggest a strong correlation between pre-trans-
plant psychosocial risk factors and patient experiences in
HSCT.281
THE IMPACT OF DONOR TYPE AND ABO INCOMPATIBILITY ON TRANSFU-
SION REQUIREMENTS AFTER NONMYELOABLATIVE HEMATOPOIETIC
CELL TRANSPLANTATION (HCT)
Wang, Z.1, Sorror, M.L.1,3, Leisenring, W.1,2,4, Schoch, G.1,2,
Maloney, D.1,3, Sandmaier, B.M.1,3, Storb, R.1,3 1Fred Hutchinson Can-
cer Research Center, Seattle, WA; 2Fred Hutchinson Cancer Research
Center, Seattle, WA; 3School of Medicine, University of Washington, Se-
attle, WA; 4School of Public Health and Community Medicine, University
of Washington, Seattle, WA
We retrospectively analyzed transfusion requirements within the
first 100 days among 503 allogeneic HCT recipients with hemato-
logical malignancies given nonmyeloablative conditioning. We
compared transfusion needs among recipients given grafts 1)
